Abcam plc: Consultation on 2020 LTIP Awards

By Dr. Matthew Watson

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation with shareholders on the Group’s overall LTIP structure and performance framework, including proposed changes for this year’s awards, it has determined to retain the existing LTIP metrics and targets contained in Abcam’s current Remuneration Policy, as approved by shareholders in 2018.

Read the original here:
Abcam plc: Consultation on 2020 LTIP Awards

Related Post


categoriaGlobal News Feed commentoComments Off on Abcam plc: Consultation on 2020 LTIP Awards | dataNovember 3rd, 2020

About...

This author published 5432 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024